Skip to main content
TME Pharma N.V. logo

TME Pharma N.V. — Investor Relations & Filings

Ticker · ALTME ISIN · NL0015000YE1 LEI · 724500EPNADXWZ58U595 Euronext Growth Manufacturing
Open in API
Filings indexed 220 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country NL Netherlands
Listing Euronext Growth ALTME

About TME Pharma N.V.

https://www.tmepharma.com/

TME Pharma N.V. is a clinical-stage biotechnology company developing novel therapies for aggressive cancers by targeting the tumor microenvironment (TME). The company's proprietary technology focuses on neutralizing chemokines within the TME to break down the tumor's protective barriers and inhibit its repair mechanisms. This approach is designed to work in combination with other treatments, such as radiotherapy and immunotherapy, to enhance their therapeutic impact. TME Pharma's lead clinical programs are concentrated on difficult-to-treat cancers, including glioblastoma and pancreatic cancer. Its lead candidate, NOX-A12, has shown promising results in clinical trials for glioblastoma, demonstrating a statistically significant improvement in patient survival when combined with standard-of-care therapies.

Recent filings

Filing Released Lang Actions
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS ET SON RAPPORT ANNUEL
Regulatory Filings
2026-04-30 French
TME Pharma publishes its annual financial results and annual report
Regulatory Filings
2026-04-30 English
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12
Regulatory Filings Classification · 60% confidence The text is a corporate press release announcing the publication of clinical trial results in the journal Nature Communications. It is not a formal financial report (e.g., 10-K, quarterly report), not an earnings release, not a capital-markets transaction, not board changes, not a proxy statement, etc. It does not match any of the specialized categories, so it falls into the general regulatory announcement/fallback category: RNS.
2026-04-16 French
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the publication of a scientific article in Nature Communications, not a financial report, earnings release, call transcript, regulatory vote, or management change. It does not present financial statements or attached regulatory filings; it is a general investor/market announcement. This falls into the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as RNS.
2026-04-16 English
TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS
Capital/Financing Update Classification · 95% confidence The document is a press release from TME Pharma announcing the extension of loan agreements and the modification of warrant terms to improve the company's financial runway. This falls under 'Capital/Financing Update' as it details debt restructuring, fundraising, and changes to the capital structure (warrants/shares). It is not a report publication announcement (RPA) because it provides the substantive details of the financial transaction rather than just announcing the availability of a report.
2026-03-09 French
TME Pharma extends financial runway to over 12 months
Capital/Financing Update Classification · 95% confidence The document is a press release from TME Pharma announcing the extension of loan maturity dates and the issuance of additional warrants to lenders. This constitutes a change in the company's capital structure and financing arrangements. According to the provided definitions, updates on company financing activities and capital structure changes fall under the 'Capital/Financing Update' (CAP) category.
2026-03-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.